Back to News
Market Impact: 0.25
Lundbeck announces headline results from Phase IV THRIVE trial evaluating VYEPTI® (eptinezumab) following inadequate response to prior CGRP-targeting preventive therapy
Source: PR Newswire
Healthcare & Biotech
The Phase IV THRIVE trial met its primary endpoint for eptinezumab, with 60% of adult migraine participants reporting they were "much improved" or "very much improved" after treatment. The prospective clinical data support the use of eptinezumab in migraine, representing a favorable but limited clinical update rather than a transformative regulatory or commercial event.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.45
More News
- One of our most recent defensive buys cleared a hurdle and its stock jumped
- Cullinan initiates FDA filing for lung cancer drug zipalertinib
- Moderna to replace Warner Bros Discovery on Nasdaq 100
- Why McKesson Stock Soared More Than 5% Higher Today
- This biotech making precision medicines for cancer could nearly triple, says JPMorgan
- The Dow's rough month, Micron's revenue surge, Google launches Gemini 4 and more in Morning Squawk
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Introducing AllMind: A New Data & AI Workspace for Institutional Investors
- AI Tools for Private Equity Due Diligence: A Buyer Workflow